Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px
Collaboration › Details

Inceptor Bio–Ori Biotech: CAGT manufacturing technology, 202212– collab early access to Ori Biotech’s fully automated CGT manufacturing platform


Period Period 2022-12-15
Organisations Partner, 1st Inceptor Bio (US)
  Partner, 2nd Oribiotech Ltd. (d/b/a Ori Biotech)
  Group Ori Biotech (Oribiotech) (Group)
Product Product  cell therapy

Ori Biotech Ltd.. (12/15/22). "Press Release: Ori Biotech and Inceptor Bio Partner to Accelerate Solid Tumor Cell Therapy Access". London & Morrisville, NC.

Inceptor joins Ori’s LightSpeed Early Access Program (LEAP) to future proof manufacturing capabilities, ahead of its first clinical trials in 2024

Ori Biotech (Ori), a leader in cell and gene therapy (CGT) manufacturing technologies, and Inceptor Bio, a next-gen cell therapy biotechnology company, have announced a new partnership to utilize Ori Biotech’s manufacturing platform technology and expertise to support initial process development through scale-up for manufacturing of Inceptor’s novel CAR-M, CAR-T and CAR-NK programs. Inceptor Bio is the third partner to join Ori’s LightSpeed Early Access Program (LEAP), granting pre-commercial access to Ori Biotech’s fully automated CGT manufacturing platform and digital capabilities.

“Our partnership with Inceptor Bio reinforces our shared mission to expand patient access to potentially curative cell therapies. Working with a fit for purpose technology platform from the process development stage is necessary to support a seamless transition to clinical and ultimately commercial scale manufacturing. We are excited to work with the Inceptor Bio team to support their work on novel mechanisms to treat difficult-to-cure cancers.,” said Jason C. Foster, Ori Biotech’s CEO.

“We’re delighted to partner with Ori Biotech as we move into the next stage of our development journey. The flexibility of the platform, coupled with real-time data flow, not only empowers us to make data driven decisions around our process, but also provides a clear path forward to commercial manufacturing at scale. Ori Biotech’s novel technology will allow us to accelerate our process development, ahead of our upcoming clinical trials,” said Shailesh Maingi, Founder and CEO of Inceptor Bio. “Ori’s team brings vast expertise in cell therapy manufacturing, and the flexibility of their technology will be key to maximizing the capabilities of our Advanced Manufacturing Platform (AMP+) in our new CGT manufacturing facility.”

About Inceptor Bio

Inceptor Bio is a biotechnology company developing multiple next-generation cell therapy products to deliver cures for underserved and difficult-to-treat cancers. Inceptor Bio is developing CAR-T, CAR-M, and CAR-NK platforms to generate a diversified pipeline to strategically treat a broad range of solid tumors. Inceptor Bio is headquartered in the Research Triangle Park area in Morrisville, North Carolina.

Contact Information

For Ori Biotech:
IB Communications
Mark Zipkin/Michelle Boxall
Tel: +44 (0) 208 943 4685

For Inceptor Bio:
Abe Maingi

Record changed: 2023-01-28


Picture BIO.NRW Greener Manufacutring Show 2023 Köln 650x200px

More documents for Inceptor Bio (US)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture BIO.NRW Greener Manufacutring Show 2023 Köln 650x300px

» top